[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
One platform, three diseases, and a body of intellectual property built to protect all three at once.
Glafabra's patent position covers the Live-cel approach across its lysosomal storage disorder programs — Fabry (GT-GLA-S03), Pompe (GT-GAA-S04), and Gaucher (GT-GBA1-S05) — because the underlying platform (correct the HSC, let cross-correction do the rest) is the same regardless of which gene gets swapped in.
That's a different kind of moat than a single-molecule company has: protect the platform, and every additional indication becomes cheaper to defend.
For anyone who's built IP strategy around a platform instead of a single asset: what would you tell a team doing this for the first time?
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0